663 research outputs found
A pharmacodynamic comparison of prasugrel vs. high-dose clopidogrel in patients with type 2 diabetes mellitus and coronary artery disease: results of the Optimizing anti-Platelet Therapy In diabetes MellitUS (OPTIMUS)-3 Trial
Aims: Patients with diabetes mellitus (DM) have increased platelet reactivity and reduced platelet response to clopidogrel compared with patients without DM. Prasugrel, a more potent antiplatelet agent, is associated with greater reductions in ischaemic events compared with clopidogrel, particularly in patients with DM. The aim of this study was to perform serial pharmacodynamic assessments of prasugrel with high-dose clopidogrel in patients with DM.
Methods and results: Optimizing anti-Platelet Therapy In diabetes MellitUS (OPTIMUS)-3 was a prospective, randomized, double-blind, crossover study in patients with type 2 DM and coronary artery disease (CAD). Patients (n= 35) were randomly assigned to either prasugrel 60 mg loading dose (LD)/10 mg maintenance dose (MD) or clopidogrel 600 mg LD/150 mg MD over two 1-week treatment periods separated by a 2-week washout period. Platelet function was assessed by VerifyNowÂź P2Y12 assay, light transmission aggregometry, and vasodilator-stimulated phosphoprotein phosphorylation at 0, 1, 4, and 24 h and 7 days. Greater platelet inhibition by VerifyNowÂź P2Y12 was achieved by prasugrel compared with clopidogrel at 4 h post-LD (least squares mean, 89.3 vs. 27.7%, P< 0.0001; primary endpoint). The difference in platelet inhibition between prasugrel and clopidogrel was significant from 1 h through 7 days (P < 0.0001). Similar results were obtained using all other platelet function measures. Prasugrel resulted in fewer poor responders at all time points irrespective of definition used.
Conclusion: In patients with type 2 DM and CAD, standard-dose prasugrel is associated with greater platelet inhibition and better response profiles during both the loading and maintenance periods when compared with double-dose clopidogrel
Identifiction and assay of synchrotron radiation-induced alterations on metalloenzymes and proteins
An updated overview of the geographic and bathymetric distribution of Savalia savaglia
The distribution of gold coral Savalia savaglia is modified on the basis of bibliographic information and recent occurrence data, collected using a ROV (Remotely Operated Vehicle) and SCUBA divers. The species is long-lived, rare and has been exploited in the past by divers for collection purposes. S. savaglia is listed in Annex II of the SPA/BD Protocol of the Barcelona Convention and has a wider distribution than previously thought, including both the Mediterranean Sea and the Atlantic Ocean. Our results highlighted that specimens mainly live at a depth range of 15-90 m, but may reach as deep as 900 m in the Mediterranean Sea. This species can form monospecific facies of hundreds of colonies, as observed in Montenegro (Adriatic Sea), between 10 and 20 m, and in the Canary Islands, at a depth range of 27-70 m. Recent data highlighted numerous cases of specimens that were endangered by lost fishing gear, which exposed this species to further threats. Considering its longevity and structural role, it is urgent to develop an effective protection measure for S. savaglia, thereby increasing research efforts and implementing protection areas for this species
An updated overview of the geographic and bathymetric distribution of Savalia savaglia
The distribution of gold coral Savalia savaglia is modified on the basis of bibliographic information and recent occurrence data, collected using a ROV (Remotely Operated Vehicle) and SCUBA divers. The species is long-lived, rare and has been exploited in the past by divers for collection purposes. S. savaglia is listed in Annex II of the SPA/BD Protocol of the Barcelona Convention and has a wider distribution than previously thought, including both the Mediterranean Sea and the Atlantic Ocean. Our results highlighted that specimens mainly live at a depth range of 15-90 m, but may reach as deep as 900 m in the Mediterranean Sea. This species can form monospecific facies of hundreds of colonies, as observed in Montenegro (Adriatic Sea), between 10 and 20 m, and in the Canary Islands, at a depth range of 27-70 m. Recent data highlighted numerous cases of specimens that were endangered by lost fishing gear, which exposed this species to further threats. Considering its longevity and structural role, it is urgent to develop an effective protection measure for S. savaglia, thereby increasing research efforts and implementing protection areas for this species
MRP4 over-expression has a role on both reducing nitric oxide-dependent antiplatelet effect and enhancing ADP induced platelet activation
The impact of inhibition of multidrug resistance protein 4 (MRP4) on nitric oxide (NO) resistance and on ADP-induced platelet aggregation is unknown. The aim of this investigation was to verify whether platelet NO resistance correlates with MRP4 expression and evaluate whether this can be reduced by in vitro MRP4 inhibition mediated by cilostazol. Moreover, we assessed if inhibition of MRP4-mediated transport reduces ADP-induced platelet reactivity. The inhibitory effect of sodium nitroprusside (SNP), a NO-donor that enhances cyclic guanosine monophosphate (cGMP) cytosolic concentration, was assessed in platelets obtained from aspirin treated patients and in a control population. The inhibitory effect of SNP was evaluated by ADP-induced aggregation in SNP-treated platelets. The impact of MRP4 on ADP-induced platelet aggregation was performed in high on aspirin residual platelet reactivity (HARPR) patients and compared to healthy volunteers (HV), and a control cohort (CTR). In aspirin-treated patients with high levels of MRP4, reduced SNP inhibition was found compared to those with low levels of MRP4. MRP4 inhibition by cilostazol significantly reduced ADP-induced platelet aggregation in HARPR population, and to a lesser extent in HV and CTR populations. In conclusion, cilostazol can mitigate the hyper-reactive platelet phenotype of HARPR patients by reducing residual ADP-induced platelet aggregation and increasing NO-dependent endothelial antiplatelet effects
Persistence of pristine deep-sea coral gardens in the Mediterranean Sea (SW Sardinia)
Leiopathes glaberrima is a tall arborescent black coral species structuring important facies of the deep-sea rocky bottoms of the Mediterranean Sea that are severely stifled by fishing activities. At present, however, no morphological in vivo description, ecological characterization, age dating and evaluation of the possible conservation actions have ever been made for any population of this species in the basin. A dense coral population was reported during two Remotely Operated Vehicle (ROV) surveys conducted on a rocky bank off the SW coasts of Sardinia (Western Mediterranean Sea). L. glaberrima forms up to 2 m-tall colonies with a maximal observed basal diameter of nearly 7 cm. The radiocarbon dating carried out on a colony from this site with a 4 cm basal diameter revealed an approximately age of 2000 years. Considering the size-frequency distribution of the colonies in the area it is possible to hypothesize the existence of other millennial specimens occupying a supposedly very stable ecosystem. The persistence of this ecosystem is likely guaranteed by the heterogeneous rocky substrate hosting the black coral population that represents a physical barrier against the mechanical impacts acted on the surrounding muddy areas, heavily exploited as trawling fishing grounds. This favorable condition, together with the existence of a nursery area for catsharks within the coral ramifications and the occurrence of a meadow of the now rare soft bottom alcyonacean Isidella elongata in small surviving muddy inclaves, indicates that this ecosystem have to be considered a pristine Mediterranean deep-sea coral sanctuary that would deserve special protection
Safety and Efficacy of Double Antithrombotic Therapy With NonâVitamin K Antagonist Oral Anticoagulants in Patients With Atrial Fibrillation Undergoing Percutaneous Coronary Intervention: A Systematic Review and MetaâAnalysis
Background
The optimal antithrombotic therapy for patients with atrial fibrillation undergoing percutaneous coronary intervention is a topic of debate. We aimed at defining the efficacy and safety of double antithrombotic therapy with single antiplatelet therapy (SAPT) plus a nonâvitamin K antagonist oral anticoagulant (NOAC) against triple antithrombotic therapy with dual antiplatelet therapy (DAPT) added to a vitamin K antagonist (VKA), illustrating the pooled cumulative distribution of events, the ranking of different NOACs tested in NOAC+SAPT combination strategies, and the state of the current evidence in the field.
Methods and Results
Randomized controlled trials meeting the inclusion criteria were identified. The primary efficacy end point was the composite of trialâdefined major adverse cardiac events. The primary safety end point was clinically significant bleeding. Secondary end points were the components of primary end points. Trialâlevel pairwise and Bayesian network metaâanalyses, reconstructed KaplanâMeier analyses, and trial sequential analysis were performed. Four randomized controlled trials (10 969 patients) were included. No differences were found in terms of major adverse cardiac events (hazard ratio [HR], 1.07; 95% CI, 0.94â1.22), and the NOAC+SAPT strategy showed a lower rate of clinically significant bleeding compared with VKA + DAPT (HR, 0.56; 95% CI, 0.39â0.80). These results were consistent in reconstructed KaplanâMeier analyses. In the Bayesian network metaâanalysis, different NOACs displayed diverse riskâbenefit profiles. Trial sequential analyses suggest that the evidence for the similarity in major adverse cardiac events compared with VKA + DAPT and the bleeding risk reduction observed with NOAC+SAPT is likely to be conclusive.
Conclusions
NOAC+SAPT does not increase the risk of major adverse cardiac events and reduces the risk of bleeding compared with VKA + DAPT in AF patients undergoing percutaneous coronary intervention. Various NOACs may have different riskâbenefit profiles in combination strategies.
Registration
URL:
https://www.crd.york.ac.uk/prospero/
; Unique identifier: CRD42020151089
Association between insulin receptor substrate-1 polymorphisms and high platelet reactivity with clopidogrel therapy in coronary artery disease patients with type 2 diabetes mellitus
Genomic characterization of pediatric Bâlymphoblastic lymphoma and Bâlymphoblastic leukemia using formalinâfixed tissues
BackgroundRecurrent genomic changes in Bâlymphoblastic leukemia (BâALL) identified by genomeâwide singleânucleotide polymorphism (SNP) microarray analysis provide important prognostic information, but gene copy number analysis of its rare lymphoma counterpart, Bâlymphoblastic lymphoma (BâLBL), is limited by the low incidence and lack of fresh tissue for genomic testing.ProcedureWe used molecular inversion probe (MIP) technology to analyze and compare copy number alterations (CNAs) in archival formalinâfixed paraffinâembedded pediatric BâLBL (n = 23) and BâALL (n = 55).ResultsSimilar to BâALL, CDKN2A/B deletions were the most common alteration identified in 6/23 (26%) BâLBL cases. Eleven of 23 (48%) BâLBL patients were hyperdiploid, but none showed triple trisomies (chromosomes 4, 10, and 17) characteristic of BâALL. IKZF1 and PAX5 deletions were observed in 13 and 17% of BâLBL, respectively, which was similar to the reported frequency in BâALL. Immunoglobulin light chain lambda (IGL) locus deletions consistent with normal light chain rearrangement were observed in 5/23 (22%) BâLBL cases, compared with only 1% in BâALL samples. None of the BâLBL cases showed abnormal, isolated VPREB1 deletion adjacent to IGL locus, which we identified in 25% of BâALL.ConclusionsOur study demonstrates that the copy number profile of BâLBL is distinct from BâALL, suggesting possible differences in pathogenesis between these closely related diseases.Peer Reviewedhttps://deepblue.lib.umich.edu/bitstream/2027.42/137353/1/pbc26363.pdfhttps://deepblue.lib.umich.edu/bitstream/2027.42/137353/2/pbc26363_am.pd
Variability of Individual Platelet Reactivity Over Time in Patients Treated With Clopidogrel Insights From the ELEVATEâTIMI 56 Trial
AbstractBackgroundThe degree of antiplatelet response to clopidogrel has been associated with clinical outcomes. Studies have investigated whether adjustment of antiplatelet therapies based on a single platelet function test is beneficial.ObjectivesThe aim of the study was to test the stability of platelet reactivity measurements over time among patients treated with standard and double doses of clopidogrel.MethodsThe ELEVATEâTIMI 56 (Escalating Clopidogrel by Involving a Genetic StrategyâThrombolysis In Myocardial Infarction 56) investigators genotyped 333 patients with coronary artery disease and randomized them to various clopidogrel regimens. Patients with at least 2 platelet function results on the same maintenance dose of clopidogrel (75 mg or 150 mg) were analyzed. Platelet aggregation was measured using P2Y12 reaction units (PRU).ResultsIn total, the mean platelet reactivity and the total number of nonresponders (PRU â„230) with clopidogrel did not change between 2 periods for the 75-mg (22.4% vs. 21.9%; p = 0.86) and 150-mg doses of clopidogrel (11.5% vs. 11.5%; p = 1.00). In contrast, when evaluating each patient individually, 15.7% of patients taking clopidogrel 75 mg and 11.4% of patients taking 150 mg had a change in their responder status when tested at 2 different time points (p < 0.001). Despite being treated with the same dose of clopidogrel, >40% of patients had a change in PRU >40 on serial sampling, which approximates the average PRU difference caused by increasing the clopidogrel dose from 75 mg to 150 mg.ConclusionsMeasurements of platelet reactivity vary over time in a significant proportion of patients. Thus, treatment adjustment according to platelet function testing at a single time point might not be sufficient for guiding antiplatelet therapy in clinical or research settings. (Escalating Clopidogrel by Involving a Genetic StrategyâThrombolysis In Myocardial Infarction 56 [ELEVATEâTIMI 56]; NCT01235351
- âŠ